Skip to main content

SparVax FDA Approval Status

FDA Approved: No
Brand name: SparVax
Generic name: recombinant Protective Antigen (rPA) anthrax vaccine
Dosage form: Injection
Company: PharmAthene, Inc.
Treatment for: Anthrax Prophylaxis

SparVax is a novel second generation recombinant protective (rPA) anthrax vaccine being developed for administration by intramuscular injection.

Development timeline for SparVax

May 26, 2009PharmAthene Submits SparVax Regulatory Strategy to FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.